- Home
- CNOBP vs GALT Comparison
CNOBP vs GALT Comparison
Compare CNOBP & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNOBP
- GALT
- Stock Information
- Founded
- CNOBP N/A
- GALT 2000
- Country
- CNOBP United States
- GALT United States
- Employees
- CNOBP 493
- GALT N/A
- Industry
- CNOBP Major Banks
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- CNOBP Finance
- GALT Health Care
- Exchange
- CNOBP Nasdaq
- GALT Nasdaq
- Market Cap
- CNOBP N/A
- GALT 83.5M
- IPO Year
- CNOBP N/A
- GALT N/A
- Fundamental
- Price
- CNOBP $23.09
- GALT $2.52
- Analyst Decision
- CNOBP
- GALT Buy
- Analyst Count
- CNOBP 0
- GALT 2
- Target Price
- CNOBP N/A
- GALT $6.00
- AVG Volume (30 Days)
- CNOBP N/A
- GALT 1.5M
- Earning Date
- CNOBP N/A
- GALT 08-12-2025
- Dividend Yield
- CNOBP N/A
- GALT N/A
- EPS Growth
- CNOBP N/A
- GALT N/A
- EPS
- CNOBP N/A
- GALT N/A
- Revenue
- CNOBP N/A
- GALT N/A
- Revenue This Year
- CNOBP N/A
- GALT N/A
- Revenue Next Year
- CNOBP N/A
- GALT N/A
- P/E Ratio
- CNOBP N/A
- GALT N/A
- Revenue Growth
- CNOBP N/A
- GALT N/A
- 52 Week Low
- CNOBP N/A
- GALT $0.73
- 52 Week High
- CNOBP N/A
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- CNOBP 57.87
- GALT 63.30
- Support Level
- CNOBP $22.86
- GALT $2.07
- Resistance Level
- CNOBP $23.08
- GALT $2.36
- Average True Range (ATR)
- CNOBP 0.12
- GALT 0.27
- MACD
- CNOBP 0.00
- GALT -0.01
- Stochastic Oscillator
- CNOBP 87.76
- GALT 61.64
About CNOBP ConnectOne Bancorp Inc. Depositary Shares each representing a 1/40th interest in a share of 5.25% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock Series A
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.